Search Results
Molecular profiling to identify druggable targets in mCRPC
Key Data on mCRPC from ASCO GU 2017: Chemotherapy for Newly Diagnosed Patients & Molecular Profiling
Targeting genetic variants in mCRPC to improve survival outcomes
ASCO 2013 - Brian Van Tine M.D., PH.D., Molecular Profiling
The Profound Trial - Lynparza in HRRm mCRPC
Prognostic biomarkers to guide treatment of mCRPC
Radionuclide conjugates 225Ac-J591 and 177Lu-PSMA-I&T for mCRPC
Genomic profiling: Finding a cure for advanced prostate cancer
The Role of Molecular Markers in Bladder Cancer
Yale Genetics Seminar 9/27/22 | Dr. Ekta Khurana PhD | Cancer evolution...
M1 CRPC: Treatment Sequencing and Future Directions
Targeting AR in Castration Resistant Prostate Cancer
